SILENCE THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1992-01-01
- Employees
- -
- Market Cap
- $889.1M
- Website
- http://www.silence-zone.com/
Clinical Trials
15
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- Conditions
- Lipoprotein(a)AtherosclerosisCardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Silence Therapeutics plc
- Target Recruit Count
- 180
- Registration Number
- NCT05537571
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Monash Health, Melbourne, Australia
🇦🇺Linear Clinical Research, Nedlands, Australia
Study to Assess SLN124 in Patients With Polycythemia Vera
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Silence Therapeutics plc
- Target Recruit Count
- 65
- Registration Number
- NCT05499013
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
- Conditions
- Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic SyndromeVery-Low Risk Myelodysplastic Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Silence Therapeutics plc
- Target Recruit Count
- 44
- Registration Number
- NCT04718844
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Düsseldorf, Germany
🇩🇪Universitat Leipzig, Leipzig, Germany
🇮🇱Rambam Health Care Campus, Haifa, Israel
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
- Conditions
- HyperlipidemiasDyslipidemiasElevated Lp(a)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Silence Therapeutics plc
- Target Recruit Count
- 70
- Registration Number
- NCT04606602
- Locations
- 🇺🇸
Jacksonville Center for Clinical Research Ltd., Jacksonville, Florida, United States
🇺🇸Progressive Medical Research, Port Orange, Florida, United States
🇺🇸Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States
A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Silence Therapeutics plc
- Target Recruit Count
- 24
- Registration Number
- NCT04559971
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
- Prev
- 1
- 2
- Next
News
Silence Therapeutics Reports Promising Phase 1 Data for Divesiran in Polycythemia Vera at EHA 2025
Silence Therapeutics presented updated Phase 1 data for divesiran at EHA 2025, showing the siRNA therapy essentially eliminated the need for phlebotomies in 21 polycythemia vera patients with a combined history of 79 prior phlebotomies.
Eli Lilly's Lepodisiran Shows 95% Reduction in Lipoprotein(a), Offering New Hope for South Asian Heart Patients
Eli Lilly's experimental drug lepodisiran demonstrated up to 95% reduction in lipoprotein(a) levels with a single 400mg dose in midstage trials, potentially addressing a significant cardiovascular risk factor prevalent in South Asian populations.
Silence Therapeutics Halts Phase III Development of Zerlasiran, Seeks Partnership for Cardiovascular Drug
Silence Therapeutics has paused the Phase III development of zerlasiran, its RNA-silencing therapy for cardiovascular diseases, until securing a strategic partnership, extending their cash runway into 2027.
Zerlasiran Shows Durable Lp(a) Reduction in ALPACAR-360 Trial
Zerlasiran, a gene-silencing therapy, demonstrated sustained reductions in lipoprotein(a) [Lp(a)] levels through 60 weeks in the ALPACAR-360 trial.
Zerlasiran Shows Significant Lipoprotein(a) Reduction in Phase 2 Trial
Zerlasiran, a novel siRNA, significantly reduced time-averaged lipoprotein(a) levels by over 80% in a Phase 2 trial, offering a potential treatment for elevated Lp(a).
Zerlasiran Demonstrates Significant Lipoprotein(a) Reduction in Phase II Trial
Zerlasiran, a GalNAc-conjugated siRNA, significantly reduced lipoprotein(a) levels by 80-85% in patients at high risk of atherosclerotic cardiovascular disease.
Zerlasiran Shows Promise in Phase II Trial for Elevated Lipoprotein(a)
Zerlasiran, a GalNAc-conjugated siRNA, significantly reduced lipoprotein(a) levels in patients at high risk of atherosclerotic cardiovascular disease.
Lilly's Muvalaplin and Silence's Zerlasiran Show Promise in Lowering Lipoprotein(a) in Phase II Trials
Eli Lilly's oral drug muvalaplin reduced lipoprotein(a) levels by up to 86% in adults with cardiovascular risk factors, meeting its primary endpoint.
Zerlasiran Shows Cumulative Lp(a) Reduction in Phase 2 Trial
Zerlasiran, a small interfering RNA (siRNA), significantly reduced lipoprotein(a) [Lp(a)] levels in a Phase 2 trial, showing over 80% reduction over 36 weeks.
Lp(a)-Lowering Therapies Show Promise in Phase II Trials
• Zerlasiran, a siRNA therapy, demonstrated an 85% reduction in Lp(a) levels over 36 weeks in the ALPACAR-360 trial, showing promise for ASCVD patients. • Muvalaplin, an oral agent, reduced Lp(a) by up to 85% in the KRAKEN trial, offering a potential alternative to injectable therapies for high Lp(a). • Both therapies were well-tolerated in phase II studies, with no significant safety concerns, marking a step forward in addressing unmet needs for Lp(a) lowering. • Clinical trials for both drugs are ongoing, with results expected in 2025 and 2026, which will determine whether lowering Lp(a) reduces cardiovascular events.